Mouse mammary tumor virus (MMTV) infection causes a high incidence of murine mammary carcinomas by insertion of its proviral DNA in the genome of mammary epithelial cells. Retroviral insertion can activate flanking proto-oncogenes by a process called insertional mutagenesis. By sequencing the DNA adjacent to MMTV proviral insertions in mammary tumors from BALB/c mice infected with C3H-MMTV, we have found a common MMTV insertion site in the Fgf10 locus. RT-PCR studies showed that Fgf10 is expressed only in those tumors harboring a MMTV proviral insertion in this locus, suggesting that Fgf10 is a proto-oncogene. The oncogenicity of Fgf10 was evaluated in vivo by subcutaneous transplantation of retrovirally transduced HC11 mammary epithelial cells into BALB/c mice. Highly vascularized invasive subcutaneous tumors developed indicating that Fgf10 can act as an oncogene. A survey of primary human breast carcinomas revealed strongly elevated Fgf10 mRNA levels in approximately 10% of the tumors tested, suggesting that Fgf10 may also be involved in oncogenicity of a subset of human breast cancers.
Introduction
The mouse mammary tumor virus (MMTV) is an efficient mutagen that can cause mammary tumors upon insertion of its proviral genome adjacent to a protooncogene in mammary epithelial cells. This allows the promoter and/or enhancer sequences within the proviral long terminal repeat (LTR) to activate inappropriately transcription of flanking cellular proto-oncogenes, although other mechanisms of activation have also been reported (for a review see Jonkers and Berns, 1996; Callahan and Smith, 2000) . Since the activated oncogene is now tagged by the inserted proviral MMTV, the integration site can be identified using various PCR techniques. From the first MMTV screens, performed in the 1980s, it became evident that MMTV mainly activates members of the wingless and the fibroblast growth factor (FGF) families, notably Wnt1/Int1, Wnt3/ Int4, Wnt10b, Fgf3/Int2, Fgf4/hst and Fgf8/AIGF (Nusse and Varmus, 1982; Peters et al., 1983 Peters et al., , 1989 Roelink et al., 1990; Lee et al., 1995; MacArthur et al., 1995) . Also Int3, a notch family gene (Gallahan and Callahan, 1987) , Int5, an aromatase gene (Morris et al., 1991) , and Int6, encoding a subunit of the translation initiation factor eIF3 (Asano et al., 1997) have been identified, but these genes seem to be less commonly activated or only activated in specific mouse strains (Int3). In fact, a Wnt and/or Fgf gene is activated in most, if not all, MMTVinduced mouse mammary tumors.
The Fgf family members are highly conserved among vertebrates, and fulfill essential roles in embryonic development, angiogenesis, tissue remodeling, homeostasis and cancer, by regulating cell proliferation, migration and differentiation (reviewed by Ornitz and Itoh, 2001 ). Fgf's are responsible for the epithelialmesenchymal communication by acting in a paracrine manner, for example, Fgf7 and Fgf10 are expressed by mesenchymal cells, while their receptors are present on epithelial cells, and Fgf8 is expressed by epithelial cells, while acting on receptors on mesenchymal cells. So far, only Fgf3, Fgf4 and Fgf8 have been shown to be oncogenic when overexpressed in mammary epithelial cells. Ectopic expression of these Fgf's in mammary epithelial cells, for instance, as a result of MMTV proviral insertion, will cause autocrine stimulation of their cognate receptors and uncontrolled growth (reviewed by Jackson et al., 1997; Powers et al., 2000; Spencer-Dene et al., 2001) . The oncogenic capacity of the remaining Fgf's has not been thoroughly investigated.
Until recently, identification of retroviral target genes was very laborious, and no efforts have been reported to exhaustively identify other MMTV target genes by proviral tagging. However, newly developed PCR technologies and the mouse genome sequence databases allowed efficient high-throughput screening for retrovirally tagged genes. A large number of common insertion sites (CIS) in Moloney murine leukemia virus (M-MuLV)-induced lymphomas have recently been reported (Hwang et al., 2002; Lund et al., 2002; Mikkers et al., 2002a; Suzuki et al., 2002) , highlighting the power of retroviral insertional mutagenesis. These developments urged us to start an exhaustive screening for novel oncogenes in MMTV-induced mouse mammary tumors. For this purpose, we have established an MMTVinfected BALB/c substrain (BALB/c þ strain) by fosternursing BALB/c pups to a C3H dam. The latter strain is known to transmit MMTV via the milk to its offspring (Bittner, 1939) .
Here, we show that another Fgf gene, Fgf10, can be activated by MMTV in retrovirally induced mammary tumors in BALB/c mice. Fgf10 is highly mitogenic upon expression in the immortalized HC11 mammary gland cell line in vitro, and renders these cells tumorigenic in vivo, establishing Fgf10 as a novel mammary tumor oncogene. Moreover, we compared its oncogenicity with the Wnt1 proto-oncogene, which is activated in a large proportion of MMTV induced mouse mammary tumors. We additionally show that FGF10 is highly overexpressed in a subset of human breast carcinomas.
Results

Fgf10 locus is a novel CIS for MMTV
We sequenced the flanks of MMTV proviral insertions of 40 BALB/c þ mammary tumors in order to search for CIS. Two tumors (nos. 98 and 147) revealed an insertion in the Fgf10 locus. In both tumors, the proviral MMTV DNA was inserted 5 0 of the Fgf10 start codon on chromosome 13 in the opposite transcriptional orientation of the Fgf10 reading frame. The insertions and orientations are depicted in Figure 1a . To determine the effect of these MMTV insertions, we tested the expression of the Fgf10 gene by RT-PCR (Figure 1b) . Both mammary tumors with MMTV integrations in the Fgf10 locus showed elevated transcription of the Fgf10 gene, whereas no expression was detected in tumors without MMTV insertions in the Fgf10 locus. As a positive control, we used lung tissue that is known to express Fgf10 (Beer et al., 1997) . These results show that the Fgf10 locus is a novel CIS, identifying Fgf10 as a putative oncogene and the fourth MMTV target of the fibroblast growth factor family. A survey of 47 primary MMTV-induced BALB/c mammary tumors (including the tumors tested for MMTV inserts), by RT-PCR, showed that Fgf10 was only overexpressed in the two tumors with an MMTV-tagged Fgf10 locus. Thus, the frequency of Fgf10 activation in BALB/c þ mammary tumors by MMTV tagging is 4%.
Generation of HC11 cells expressing Fgf10 and Wnt1
The potential tumorigenic properties of the Fgf10 were investigated using the HC11 cell line. HC11 is an immortalized mouse mammary epithelial cell line, which has been extensively used to study the oncogenic effect of Wnt genes in vitro and in vivo (Humphreys and Rosen, 1997) . The HC11 cells are immortalized as a result of independent spontaneous mutations in both alleles of the p53 gene (Merlo et al., 1993) .
Full-length Fgf10 cDNA was cloned into an LZRS retroviral vector containing the zeocin resistance gene as selection marker. HC11 cells were retrovirally transduced with viruses containing the empty LZRS-zeo and LZRS-Fgf10-zeo constructs. We also transduced HC11 cells with LZRS-Wnt1-neo as it is known that certain Wnt genes render these cells tumorigenic (Humphreys and Rosen, 1997) . The transduced cell cultures, denoted HC11-LZRS, HC11-Fgf10 and HC11-Wnt1, were grown in the appropriate selective medium for 2 weeks and then used for further experiments. The mRNA expression levels of the Fgf10, Wnt1 and b-actin genes in the stable cell lines were tested by RT-PCR. The b-actin mRNA levels were comparable among all three cell lines (Figure 2a ). HC11 cells transduced with the empty LZRS control virus did not show the expression of either Fgf10 or Wnt1, whereas Fgf10 and Wnt1 genes were expressed in the HC11-Fgf10 and HC11-Wnt1 cells, respectively. The presence of the FGF10 protein in the HC11-Fgf10-transduced cells was confirmed by Western blot analysis (Figure 2b ). We verified Wnt1 protein production in HC11-Wnt1 using the pTOP-FLASH/ pFOPFLASH assay (van de Wetering et al., Fgf10-expressing HC11 cells exhibit increased proliferation in vitro FGF10 is mitogenic for epithelial cells (Igarashi et al., 1998) , most likely through the activation of the MAPK pathway (Taniguchi et al., 2003) . We tested the mitogenic effect of Fgf10 expression in HC11 cells in an in vitro proliferation assay. Figure 3 shows a representative experiment (out of three independent experiments). The proliferation rate of the HC11-FGF10 cells is strongly increased compared with the HC11-LZRS and HC11-Wnt1 cells, demonstrating that FGF10 is mitogenic in these cells and indicating that an appropriate FGF receptor is present in HC11 cells. To avoid any T-cell-mediated immune response against the injected transduced HC11 cells, we repeated the experiment by subcutaneous transplantation of all three transduced HC11 cell lines in six BALB/c nu/nu mice per group (1.10 6 cells per mouse). Again the HC11-Fgf10 and HC11-Wnt1 cells gave rise to large subcutaneous malignant tumors, whereas the HC11-LZRS control cells developed barely palpable outgrowths.
FGF10 expression in human primary breast carcinomas and cell lines
In order to investigate a possible involvement of FGF10 in human breast cancer, FGF10 expression was examined in normal human breast tissue obtained from breast reduction mammoplasties and in primary breast carcinomas by RT-PCR. The tumors were randomly selected from a panel of breast cancers that were selected for a high epithelial/stroma ratio (450% epithelial cells) based on histological sections. The normal breast samples showed a low but significant level of FGF10 mRNA expression, which was expected since normal breast tissue can be comprised of more than 90% stroma and adipose tissue. Out of 50, 46 (92%) tumor samples showed a variable level of FGF10 expression by RT-PCR (data not shown).
For more quantitative analysis, we tested FGF10 expression in a selected panel of samples (which included all samples with high and some of the samples with low or moderate expression levels in the conventional PCR) using quantitative real-time PCR. Figure 6 depicts the expression levels of FGF10, relative to a standard curve and corrected for the input of cDNA, based on the b-actin control. The results were in 2, 33, 35, 36, 50) , whereas the FGF10 mRNA levels in the other tumors is in the same range or only slightly above the levels in normal breast tissue (tumors no. 51, 53, 54, 55) . We also tested a set of four breast carcinoma cell lines for FGF10 mRNA expression. Indeed, BT549 breast cancer cells also expresses FGF10, albeit at low level (results not shown).
Discussion
The Fgf10 locus emerged from our screen as a novel MMTV CIS in mouse mammary tumors. Only in those tumors in which the Fgf10 locus was tagged, transcription of the Fgf10 gene was observed, showing that the inserted MMTV proviral sequences activate the Fgf10 gene. Our in vivo experiments showed that the expression of Fgf10 in the mammary epithelial HC11 cells is sufficient for the development of moderately differentiated, highly vascularized, invasive tumors. Therefore, we conclude that Fgf10 is a novel oncogene. Fgf10 was originally identified as a novel FGF family member by a homology-based PCR amplification of rat embryo cDNA (Yamasaki et al., 1996) . Fgf10 is essential for a range of developmental processes, including lung and limb bud formation, epidermal morphogenesis, adipogenesis and mammary gland development (Min et al., 1998; Sekine et al., 1999; Suzuki et al., 2000; Mailleux et al., 2002) . In various embryonic tissues including lung and prostate, Fgf10 expression is restricted to the stroma, while its receptor, FgfR2IIIb, is present on epithelial cells, suggesting that Fgf10 orchestrates proliferation in a paracrine manner by signaling from the mesenchyme to the adjacent epithelium (Bellusci et al., 1997; Lu et al., 1999) . Despite the fact that Fgf10 plays a role in cell growth during development, it has never been implicated in cancer. However, it could be envisaged that coexpression of the mitogenic ligand, normally expressed by stroma, and its receptor in epithelial cells could have a strong tumorpromoting effect. Indeed, our data show that Fgf10 expression in mammary epithelial cells, here in conjunction with mutated p53, leads to oncogenesis.
Three other members of the FGF family, Fgf3, Fgf4 and Fgf8, are frequently activated in MMTV-induced murine mammary tumors (for a review see Dickson et al., 2000) . Like Fgf10, these FGF family members are crucial developmental regulators. In mice Fgf3 and Fgf4 are only expressed in mesenchymal cells during embryogenesis, where they signal to receptors on epithelial cells. Ectopic overexpression of these Fgf genes in the epithelial cells of the mammary gland of transgenic mice causes severe mammary hyperplasia (Stamp et al., 1992; Ngan et al., 2002) as the epithelial cells are now continuously stimulated in an autocrine manner. Although Fgf10 causes mammary tumors in a similar manner, an essential difference is that Fgf10 is also expressed in normal mammary tissue, as shown here in the human breast reduction samples. In normal tissues the availability of Fgf10, secreted by the stromal breast cells, is tightly controlled by binding to heparin and heparan-like glycosaminoglycans in cell surface proteoglycans and in the extracellular matrix surrounding the normal ductal epithelium (reviewed by Powers et al., 2000) . Therefore, stromal Fgf10 expression does not lead to continuous growth stimulation of the epithelial cells, and will normally not lead to hyperplasia and cancer. However, aberrant autocrine stimulation of the epithelial cells by FGF10 could bypass this slow and probably regulated release, and cause a strong and mitogenic stimulation leading to neoplasia.
We provide direct evidence for the oncogenic effects of Fgf10 expression in murine epithelial mammary gland cells by showing that subcutaneous injection of Fgf10-expressing HC11 cells caused malignant tumors. Although we did not investigate the contribution of the p53 mutations already present in parental HC11 cells to the tumorigenicity of the Fgf10-transduced cells, it is likely that both genes cooperate. Previously, it was reported that Wnt1-expressing HC11 cells were (Humphreys and Rosen, 1997) . The difference between these published results and our own findings may either be due to the injection site or to the expression levels of the oncogenes.
In both, the nude mice and the immunocompetent BALB/c mice, the HC11-Wnt1 tumors were larger than the HC11-Fgf10 tumors. This is most likely due to the higher proliferation rate of HC11-Wnt1 cells in vivo and not the result of infiltrating hematopoietic cells or stromal cells of host origin, which are almost absent in the HC11-Wnt1 tumors ( Figure 5 ). In contrast, the HC11-Fgf10 cells proliferate much faster in vitro (Figure 3) . The difference in proliferation rate in vitro and in vivo between the FGF10-and Wnt1-transduced cells has not been investigated, but could be due to a multitude of environmental factors (for a review see Bissell and Radisky, 2001 ) including: (a) dependence on a growth factor or otherwise support from host cells that is synergistic with Wnt1 expression; (b) the tumor cells grow in vivo in a 3D environment while in vitro in a 2D culture, which strongly can affect growth properties and differentiation. Indeed the HC11-Fgf10 tumor cells in vivo are more differentiated than the Wnt1 tumor cells and may have therefore a reduced growth rate; (c) the Wnt1 cells may be more sensitive to apoptosis in vitro; (d) differences in vascularization may affect tumor growth, but this cannot explain the difference in growth rate here, as the smaller HC11-FGF10 tumors are more vascularized.
A preliminary survey of FGF10 mRNA expression in reduction mammoplasties and human breast cancers shows that the gene is expressed in normal breast tissues and in 92% of the primary tumors. The expression in normal breast tissue is likely limited to the stromal fibroblasts; probably, this is also the case for the tumors with low levels of FGF10 expression. However, 10% of the breast carcinomas had strongly increased expression. Taking into consideration the high epithelial/stroma ratio in these carcinomas, one may suggest that FGF10 is aberrantly expressed in the epithelial component of the tumor. This notion is supported by the expression in the BT549 breast carcinoma cell line. Our observations indicate a possible role of FGF10 in human breast cancer.
The role of most other FGFs in human breast cancers is probably limited. Significant expression levels of FGF1 and FGF2, which both stimulate angiogenesis, are present in normal breast tissue, but the levels are usually lower in breast cancers (Bansal et al., 1995 (Bansal et al., , 1997 Penault-Llorca et al., 1995) . Fgf3 and Fgf4 are oncogenic in murine mammary epithelium, but their human orthologs are not expressed in any normal adult human breast tissue or human breast cancers. Expression of FGF5, FGF6 and FGF9 is infrequently found in breast cancers, but the levels seem not to be higher than in normal breast tissue (Penault-Llorca et al., 1995) . FGF7, which is highly homologous to FGF10, is also secreted by stromal breast cells and is a paracrine growth factor for breast epithelial cells; however, this factor was not found upregulated in breast carcinomas (Bansal et al., 1997) , although expression in the epithelial component of breast cancers has been reported (Palmieri et al., 2003) . Elevated expression levels of FGF8 are present in a subset of human breast cancers (Marsh et al., 1999; Tanaka et al., 2002) . As both FGF8 and some of its receptors are expressed by the epithelial component of breast cancers, an autocrine activation loop may be established that could lead to tumor progression. Interestingly, Fgf10 may regulate Fgf8 expression and vice versa during limb bud formation (Martin 1998) , which is in accordance with the notion that both factors may be involved in human breast cancer.
In conclusion, we show that a stromal factor, Fgf10, which orchestrates a variety of developmental responses, such as morphogenesis through epithelial-mesenchymal interactions, can act as an oncogene when activated by MMTV in epithelial cells in mouse mammary tumors and is strongly overexpressed in some human breast carcinomas.
Materials and methods
Mouse model
We have infected newborn BALB/c/He/A mice with MMTV by foster nursing on C3H/A females harboring the milk transmitted MMTV (Bittner, 1939) . The infected BALB/c mice develop mammary tumors with high incidence (495% before the age of 1 year) (van der Valk, 1981) . The primary tumors were collected and part of the tumors was frozen for genetic and biochemical analysis and another part was formalin fixed for histology.
Cells and antibodies
HC11 cells are derived from the COMMA-D cells, a spontaneously immortalized BALB/c mammary epithelial cell line (Danielson et al., 1984) . The HC11 cells were obtained from Dr Nancy Hynes (Friedrich Miescher Institute, Basel, Switzerland) . The cells were grown in a 1 : 1 mixture of Dulbecco's modified Eagle's medium and Ham's F12 (DM/ F12) medium supplemented with 10% fetal bovine serum (FBS), 20 ng/ml EGF and 10 mg/ml insulin. MCF-7, T47D, MDA-MB-231 and BT549 are human breast carcinoma cell lines obtained from the American type culture collection. These cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% FBS and 10 mg/ml insulin.
For immunohistochemistry the following antibodies were used: anti-cytokeratin 14 (K14), 1 : 10 000 (BabCO) and anticytokeratin 8 (K8), 1 : 1000 (BabCO). For immunoblotting: anti-b-tubulin, 1 : 1000 (Sigma) and rabbit anti-human FGF10 serum (H-121, Santa Cruz Biotechnology).
Human tissues
mRNA from four normal breast reduction mammoplasties and 50 estrogen receptor-positive and -negative primary breast carcinomas were used for conventional RT-PCR and real-time PCR. The mRNA numbers 51-55 ( Figure 6 ) were derived from normal breast reduction mammoplasties. The primary breast carcinoma specimens were randomly selected from a panel of breast cancers that were selected for a high carcinoma/stroma percentage (450%) based on histological FGF10 activation in mouse and human mammary carcinomas V Theodorou et al sections. The mRNA numbers 8-15 were obtained from metastatic tumors and the mRNA numbers between 16 and 50 were obtained from primary breast cancers (o5 cm) from lymph node-negative patients (age 455 years).
Retroviral constructs
Full-length Fgf10 cDNA was obtained by PCR amplification using Pwo Polymerase of mouse lung total cDNA. Fgf10 cDNA was subcloned in the EcoRI/EcoRI restriction sites in the LZRS-IRES-ZEO/pBR retroviral vector (LZRS-NEO) obtained from Dr J Collard, Netherlands Cancer Institute, Amsterdam. The LZRS-IRES-NEO-Wnt1 construct (LZRSWnt1-NEO) was also a gift from Dr Collard's lab.
Identification of MMTV flanking sequences
We identified the MMTV flanking sequences in the tumors using a modified Splinkerette protocol (Qureshi et al., 1994; Mikkers et al., 2002b) , which was modified for our purposes as described by V Theodorou, M Kimm,J Jonkers and J Hilkens (manuscript in preparation). Briefly, genomic DNA of the mammary tumors was digested with BstYI (cuts once in the MMTV-LTR) and linked to a splinkerette oligo. Primers complementary to the splinkerette and the MMTV-LTR were then used to amplify the 5 0 flanking sequences of proviral MMTV. The amplified tags were isolated and sequenced using the BigDye Cycle Sequencing kit (Perkin-Elmer) ABI 377 sequencer (Perkin-Elmer). The sequences were analysed using the annotated mouse genome databases at Ensembl (version 16.30.1) and Celera (release 12).
RNA isolation and cDNA generation
RNA from tumors, normal tissues and cell lines was generated using TRIzol (Invitrogen). cDNAs were synthesized from 5 mg total RNA with oligo-dT primers, using the SuperScript TM III kit, according to the manufacturer's protocol (Invitrogen).
Retroviral transduction of HC11 cells with Fgf10-and Wnt1-encoding retroviruses
We transduced HC11 cells with ecotropic retroviruses expressing Fgf10 or Wnt1, or with empty LZRS viruses (Michiels et al., 2000) . For the production of the viruses, the ecotropic packaging cell line (jNX-E) was transfected with 10 mg retroviral vector DNA using standard calcium phosphate coprecipitation. A total of 10 5 HC11 cells were plated in 6 cm dishes and left to grow until 60% confluency, before infecting with the freshly harvested virus, using Polybrene (Michiels et al., 2000) . LZRS-zeo (control) and LZRS-Fgf10-zeotransduced HC11 cells were grown for 2 weeks under the selection of 200 mg/ml zeocin (Invitrogen) and LZRS-Wnt1-neo under the selection of 200 mg/ml neomycin (G148, Invitrogen).
RT-PCR
To verify the expression of the introduced genes in the stable HC11 cell lines on the mRNA level, we performed RT-PCR for 28 cycles for Fgf10, Wnt1 and 22 cycles for b-actin using 0.5 ml of cDNA for each reaction. PCR products were run on 1% agarose gels and visualized by ethidium bromide staining. The intensities of the bands were measured using Eagle Eye IIt camera and software (Stratagene). PCR conditions for all RT-PCRs were performed as follows: denaturation at 951C for 30 s, annealing at 601C for 30 s and extension at 721C for 1 min. Primers for Fgf10: forward 5 0 -CTGGAGATAACAT 0 . RT-PCRs on the primary mouse mammary tumors and human breast tumors and cell lines were preformed using the same primers and PCR conditions as listed above, for 30 cycles unless stated otherwise.
Real-time PCR for human carcinomas
Human tumor cDNA was produced from 3 mg total RNA with oligo-dT primers, using the SuperScripttIII kit, according to the manufacturer's protocol (Invitrogen). Quantitative realtime PCR was performed using 0.25 ml cDNA per reaction of 50 PCR cycles (Bosma et al., 2002) . For FGF10, we used the same primers as in the RT-PCR, with the SYBR s Green PCR Master Mix from Applied Biosystems. As a housekeeping gene, we used the TaqMan s beta-actin Detection Reagents kit (Applied Biosystems).
pTOPFLASH/pFOPFLASH dual luciferase reporter assay
We used the TK-TOPFLASH firefly luciferase, TK-FOP-FLASH firefly luciferase and TK-RL Renilla luciferase constructs (gifts from H Clevers, Hubrecht Laboratory, Utrecht, The Netherlands) to measure the activation of the Wnt pathway in the stable transfectants (van de Wetering et al., 1997) . Cells were transfected with FuGENE 6 (Roche), and the firefly luciferase and the Renilla luciferase activities in 15 ml of lysate were measured after 24 h, using the dual luciferase reagent assay kit (Promega) in a luminometer (Berthold).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting
Cells were lysed in 1% Nonidet P40 in phosphate-buffered saline (PBS) in the presence of 10 mg/ml aprotonin and 1 mM phenylmethylsulfonyl fluoride (Sigma). A measure of 20 ml of cell lysate was separated in 15% SDS-PAGE under reducing conditions. Low-molecular-weight markers (Bio-Rad) were used for reference. The separated proteins were transferred onto a nitrocellulose membrane filter. The filter was briefly stained with Ponceau S to visualize the molecular weight markers, blocked with 5% w/v nonfat dried milk in PBST (0.05% Tween-20 in PBS) and extensively rinsed with PBS. Subsequently, the membranes were incubated with rabbit-antihuman FGF10 (H-121, Santa Cruz Biotechnology) and antitubulin (Sigma) for loading control. Bound antibodies were detected using Swine anti-rabbit IgG conjugated with peroxidase (DAKO) and the Amersham enhanced chemiluminescence kit.
Proliferation assay
A total of 5 Â 10 4 cells were plated in triplicate for each measurement in six-well plates. Cells were counted every other day during an 8-day period. Cells were detached by trypsinization and counted using the Casy 1 model TTC Cell Counter and Analyzer System (Scha¨rfe GMBH, Reutlingen, Germany) on days 2, 4, 6 and 8. The medium in the remaining wells was refreshed on each day of counting. 
Transplantation of stable transduced HC11 cells in vivo
Retrovirally transduced HC11 cells (passage five after transduction) at 80% confluency were detached with trypsin/EDTA and resuspended in DM/F12 medium containing 50% matrigel (Harbor BioProducts, Norwood, MA, USA). Five million cells in 0.2 ml 50% matrigel were subcutaneously injected into the flank of female BALB/c mice and 1 Â 10 6 cells in 50% matrigel were subcutaneously injected into BALB/c nu/nu mice.
Immunostaining of the tumors
Tumors were fixed in formalin, dehydrated and embedded in paraffin. Sections (4 mm) were stained with H&E. Immunostaining of the sections was carried out as described (Ivanyi et al., 1989) . Photographs from the sections were obtained using an Axiovert S100 Microscope and Axiocam camera (Zeiss).
